JP2006508979A5 - - Google Patents

Download PDF

Info

Publication number
JP2006508979A5
JP2006508979A5 JP2004553551A JP2004553551A JP2006508979A5 JP 2006508979 A5 JP2006508979 A5 JP 2006508979A5 JP 2004553551 A JP2004553551 A JP 2004553551A JP 2004553551 A JP2004553551 A JP 2004553551A JP 2006508979 A5 JP2006508979 A5 JP 2006508979A5
Authority
JP
Japan
Prior art keywords
heteroaryl
aryl
heterocyclyl
arylalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004553551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508979A (ja
JP4611745B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/035670 external-priority patent/WO2004046101A2/fr
Publication of JP2006508979A publication Critical patent/JP2006508979A/ja
Publication of JP2006508979A5 publication Critical patent/JP2006508979A5/ja
Application granted granted Critical
Publication of JP4611745B2 publication Critical patent/JP4611745B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004553551A 2002-11-20 2003-11-10 ErbB2及びEGFR阻害剤としてのシアノグアニジン及びシアノアミジン Expired - Fee Related JP4611745B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42754402P 2002-11-20 2002-11-20
PCT/US2003/035670 WO2004046101A2 (fr) 2002-11-20 2003-11-10 Cyanoguanidines et cyanoamidines utilisees comme inhibiteurs de erbb2 et egfr

Publications (3)

Publication Number Publication Date
JP2006508979A JP2006508979A (ja) 2006-03-16
JP2006508979A5 true JP2006508979A5 (fr) 2006-08-03
JP4611745B2 JP4611745B2 (ja) 2011-01-12

Family

ID=32326558

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004553551A Expired - Fee Related JP4611745B2 (ja) 2002-11-20 2003-11-10 ErbB2及びEGFR阻害剤としてのシアノグアニジン及びシアノアミジン

Country Status (6)

Country Link
EP (1) EP1567506A4 (fr)
JP (1) JP4611745B2 (fr)
AU (1) AU2003291394B2 (fr)
CA (1) CA2506503A1 (fr)
NZ (1) NZ540092A (fr)
WO (1) WO2004046101A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562319B2 (en) 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
JP2007502807A (ja) * 2003-08-18 2007-02-15 ファイザー・プロダクツ・インク Erbb2抗がん剤の投与スケジュール
EP1673110A2 (fr) * 2003-09-11 2006-06-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Inhibiteurs radiomarques irreversibles de la tyrosine kinase du recepteur du facteur de croissance epidermique et leur utilisation en radioimagerie et radiotherapie
CN101056639A (zh) 2004-09-15 2007-10-17 詹森药业有限公司 噻唑并吡啶激酶抑制剂
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
DE102006012251A1 (de) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
CL2007003158A1 (es) * 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
EA018716B1 (ru) 2007-10-29 2013-10-30 Натко Фарма Лимитед Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств
BRPI1015363A2 (pt) 2009-07-02 2015-08-25 Newgen Therapeutics Inc Compostos de quinazolina contendo fósforo, uso dos mesmos, composição e kit
EP2956138B1 (fr) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Composés thérapeutiques et utilisations de ceux-ci
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
EP3402536A4 (fr) 2016-01-13 2019-07-03 Hadasit Medical Research Services And Development Limited Analogues radiomarqués de l'erlotinib et leurs utilisations
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110953B1 (fr) * 1995-03-30 2009-10-28 Pfizer Products Inc. Dérivés de quinazolinone
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0880508B1 (fr) * 1996-02-13 2003-04-16 AstraZeneca AB Derives de la quinazoline utilises comme inhibiteurs du vegf
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AU3053999A (en) * 1998-03-31 1999-10-25 Kyowa Hakko Kogyo Co. Ltd. Nitrogenous heterocyclic compounds
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
DE60108754T2 (de) 2000-06-22 2005-06-23 Pfizer Products Inc., Groton Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum

Similar Documents

Publication Publication Date Title
JP2006508979A5 (fr)
JP2009515988A5 (fr)
JP2005526076A5 (fr)
JP2019104748A5 (fr)
JP2006502119A5 (fr)
JP2008510828A5 (fr)
JP2010535722A5 (fr)
JP2010507602A5 (fr)
JP2013504593A5 (fr)
JP2011513410A5 (fr)
JP2005508905A5 (fr)
JP2005533804A5 (fr)
JP2007523139A5 (fr)
JP2007524696A5 (fr)
JP2010511721A5 (fr)
JP2008545801A5 (fr)
JP2007502295A5 (fr)
JP2012504608A5 (fr)
JP2010501478A5 (fr)
JP2005503385A5 (fr)
JP2009535358A5 (fr)
JP2002512243A5 (fr)
JP2006514691A5 (fr)
JP2009537469A5 (fr)
JP2005535586A5 (fr)